GeneCentric Therapeutics, a company making precision medicine more precise through gene expression, announced the initial closing of an $8.0 million Series C financing. The funding round was led by Hatteras Venture Partners, with current participation from existing investors IAG Capital Partners, Alexandria Venture Investments, and Labcorp.

GeneCentric Therapeutics是一家通过基因表达使精准医疗更加精准的公司，宣布已完成800万美元的C轮融资的初步交割。本轮融资由Hatteras Venture Partners领投，现有投资者IAG Capital Partners、Alexandria Venture Investments和Labcorp也参与了跟投。

The financing is expected to provide a cash runway for GeneCentric through 2026..

这笔融资预计将在2026年之前为GeneCentric提供现金支持。